Comparison of Sequencing and PNA Clamping of EGFR Gene in Patients With Non-Small Cell Type Lung Cancer
NCT01767974 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 140
Last updated 2013-01-15
Summary
Using DNA acquired from tumor tissue, sequencing and PNA-clamping for EGFR gene will be performed. The detection rates of EGFR mutation will be compared using paired samples.
Conditions
Sponsors & Collaborators
- collaborator INDUSTRY
-
Chonnam National University Hospital
lead OTHER
Principal Investigators
-
Young-Chul Kim, MD, PhD · Chonnam National University Hospital
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-01-31
- Primary Completion
- 2014-12-31
- Completion
- 2015-06-30
Countries
- South Korea
More Related Trials
-
Detection of EGFR Mutations in the Blood of Patients With Non-small Cell Lung Cancer: a Feasibility Study
NCT00717002 ·Status: COMPLETED
-
Resistance & Activating Mutations Diagnosed Among NSCLC Community Dwelling EGFR Mutation Positive Patients
NCT03137264 ·Status: COMPLETED
-
Next Generation Sequencing Method for the Detection of EGFR Gene Mutations in the Plasma of Patients With Lung Cancer
NCT06595498 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Acquired Resistant Mechanism of the First-generation EGFR TKIs
NCT02804217 ·Status: UNKNOWN
-
Afatinib in Lung Cancer With EGFR Mutation From Circulating Tumor DNA
NCT02629523 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of EGFR TKIs in Patients With Rare EGFR-mutated NSCLC
NCT01775943 ·Status: UNKNOWN
-
EGFR-TKI Resistance Profile in Chinese Patients With Advanced EGFRm+ NSCLC
NCT02988141 ·Status: UNKNOWN
-
Genotype-Driven Treatment of Advanced Non-small Cell Lung Cancer Based on mRNA Expression of ERCC1 & RRM1 as First-line Chemotherapy
NCT01648517 ·Status: COMPLETED ·Phase: PHASE2
-
Frequency of EGFR and KRAS Mutations and Clinical-prognostic Correlation in Brazilian Lung Cancer Patients
NCT03171636 ·Status: COMPLETED
-
Phase I/II Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of HM61713 in NSCLC Patients
NCT01588145 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
NGS Combined With RNAseq on Tumor Immune Escape in NSCLC
NCT03764917 ·Status: UNKNOWN
-
Real World Study in Locally Advanced or Metastatic NSCLC Patients, Progressed From First-line EGFR-TKI Therapy
NCT04207775 ·Status: COMPLETED
-
EGFR Mutations on ctDNA in Patients With Advanced NSCLC
NCT02623257 ·Status: COMPLETED
-
Weekly Use First-generation EGFR-TKI in the Treatment of EGFR-TKI Acquired Resistance Non-small Cell Lung Cancer (NSCLC)
NCT02575560 ·Status: COMPLETED
-
Evaluate EGFR Mutation Status and Impact Factors in North China
NCT02620657 ·Status: COMPLETED
-
A Retrospective Study of Biomarkers in Non-Small Cell Lung Cancer
NCT01100840 ·Status: UNKNOWN
-
Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong
NCT03519958 ·Status: WITHDRAWN
-
Exploring Cancer Evolution, Prognostic and Predictive Biomarkers in EGFR-mutant NSCLC
NCT05997719 ·Status: RECRUITING
-
PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery
NCT02804776 ·Status: COMPLETED ·Phase: PHASE2
-
Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance
NCT07122882 ·Status: ENROLLING_BY_INVITATION
-
A Study to Investigate Safety, Tolerability, PK and Anti-tumor Activity of TRX-221 in EGFRm NSCLC Patients
NCT06186076 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
NGS Genome Analysis in Personalisation of Lung Cancer Treatment
NCT02281214 ·Status: COMPLETED ·Phase: NA
-
A Prospective Observational Study Evaluating c-MET Expression and EGFR Gene Mutation Correlation With Erlotinib Response
NCT01523340 ·Status: COMPLETED
-
Asia Pacific and Russia Diagnostic Study for EGFR Testing
NCT01788163 ·Status: COMPLETED ·Phase: NA
-
INHERIT EGFR - Studying Germline EGFR Mutations
NCT01754025 ·Status: ACTIVE_NOT_RECRUITING